Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Volume 142, Issue 3, Pages (September 2012)

Volume 71, Issue 2, Pages (February 2017)

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias Jorge E. Cortes, Carlo Gambacorti-Passerini,

A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma Yirui Zhai, MD, Zhouguang Hui, MD, Wei Ji, MD, Xiaozhen Wang,

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Volume 375, Issue 9722, Pages (April 2010)

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Volume 49, Issue 4, Pages (April 2006)

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers Dong Xie, MD, PhD, Randolph.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Clinical Lymphoma, Myeloma and Leukemia

A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System Jie Lin, PhD, MPH, Corey A. Carter,

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage.

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion

Clinical Relevance of Our Multimodality Prognostic Score

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Clinical Lymphoma, Myeloma and Leukemia

Primary Small Cell Carcinoma of the Esophagus

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Autologous Stem Cell Transplantation for POEMS Syndrome

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin Chen, Lei Zhou, Junbao Wei, Chunhua Wu, Xiaodong Zhu, Shixiong Liang, Song Qu Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 12, Pages e537-e543 (December 2018) DOI: 10.1016/j.clml.2018.08.011 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Kaplan-Meier OS Curve for 81 ENKTL Patients Abbreviations: ENKTL = extranodal natural killer/T-cell lymphoma; OS = overall survival. Clinical Lymphoma, Myeloma and Leukemia 2018 18, e537-e543DOI: (10.1016/j.clml.2018.08.011) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Prognosis of Patients With ENKTL. (A) OS of Patients According to AGR ≤ 1.3 Versus AGR > 1.3 (P < .05). (B) OS of Patients According to PC ≤ 153 × 109/L, PC 153∼226 × 109/L Versus PC > 226 × 109/L (P < .05). (C) OS of Patients According to ECOG PS < 2 Versus ≥ 2 (P < .05). (D) OS of Patients According to Ann Arbor Stage I/II Versus III/IV (P < .05). (E) OS of Patients According to ALC ≤ 1.32 × 109/L Versus ALC > 1.32 × 109/L (P < .05). (F) OS of Patients According to Different Treatments (P < .05) Abbreviations: AGR = albumin-to-globulin ratio; ALC = absolute lymphocyte count; CT = chemotherapy; ECOG PS = Eastern Cooperative Oncology Group performance status; ENKTL = extranodal natural killer/T-cell lymphoma; OS = overall survival; PC = platelet count; RT = radiotherapy. Clinical Lymphoma, Myeloma and Leukemia 2018 18, e537-e543DOI: (10.1016/j.clml.2018.08.011) Copyright © 2018 The Authors Terms and Conditions

Figure 3 Prognostic Nomogram for Patients With ENKTL. To Use Nomogram, Value Attributed to Individual Patient Is Located on Each Variable Axis, and a Line Is Drawn Upward to Determine Number of Points Received for Each Variable Value. Sum of These Numbers Is Located on Total Points Axis, and Line Is Then Drawn Downward to Survival Axis to Determine 1-, 3-, and 5-Year OS Likelihood Abbreviations: AGR = albumin-to-globulin ratio; ECOG = Eastern Cooperative Oncology Group performance status; ENKTL = extranodal natural killer/T-cell lymphoma; OS = overall survival; PC = platelet count. Clinical Lymphoma, Myeloma and Leukemia 2018 18, e537-e543DOI: (10.1016/j.clml.2018.08.011) Copyright © 2018 The Authors Terms and Conditions

Figure 4 Calibration Plots of OS at 1 (A), 3 (B), and 5 (C) Years. Nomogram Predicted Probability of OS Is Plotted on x-axis; Actual OS Is Plotted on y-axis. Solid Red Line Represents Our Nomogram; Blue Vertical Bars Represent 95% CI. Dashed Lines Through Origin Point Represent Perfect Prediction, in Which Predicted Probabilities Are Identical to Actual Estimated Probabilities Abbreviations: CI = confidence interval; OS = overall survival. Clinical Lymphoma, Myeloma and Leukemia 2018 18, e537-e543DOI: (10.1016/j.clml.2018.08.011) Copyright © 2018 The Authors Terms and Conditions

Figure 5 Kaplan-Meier Survival Curves According to Ann Arbor Stage (A), International Prognostic Index (B), and Korean Prognostic Index (C) Clinical Lymphoma, Myeloma and Leukemia 2018 18, e537-e543DOI: (10.1016/j.clml.2018.08.011) Copyright © 2018 The Authors Terms and Conditions